Innova Captab Limited IPO - Key Details You Need to Know
About Innova Captab
With its inception in 2006, Innova Captab has grown from strength to strength over the last 15 years and serves the top Indian pharma companies. It has a presence in 15+ countries and 2400+ CDMO products. It has two state-of-the-art manufacturing facilities that help it easily manufacture complex products. With a strong team of 1000+ employees, Innova Captab crossed Rs 3000 million in total revenue in 2019.
Financial Snapshot
Over the years, the company has demonstrated growth in its revenues, which speaks about the efficiency of its operations. Some of its key financial metrics are as follows for FY 23:
| Total Income | Rs 9,355.78 million |
|---|---|
Total Expenses | Rs 8,437.83 million |
Total Assets | Rs 7,044.14 million |
Total Liabilities | Rs 4,279.08 million |
Return on Net Worth | 24.58% |
IPO Details
Innova Captab's IPO comprises fresh equity shares worth up to Rs 400 crore, while the offer for sale will have 9,600,000 equity shares. Given below are some of the other details of the IPO:
| IPO Subscription Opens On | 21 December |
|---|---|
IPO Subscription Ends On | 26 December |
Price Band | Rs 426 - 448 per share |
Lot Size | 33 shares and in multiples thereafter |
With the funds obtained from the IPO, the company plans to:
- Repay certain outstanding loans
- Fund working capital requirements
- Invest in its subsidiary UML
It plans to use the remaining amount for general corporate purposes.
How to Apply for Innova Captab Limited IPO
Kotak Securities makes it easy for you to apply for this IPO. All you need to do is:
- Log into the Demat account you have with Kotak Securities
- Hover to the current IPO section
- Input the IPO details, including the number of lots, and specify your desired price for application
- Provide your UPI ID and then click on submit to place your bid
- You will get a notification on your UPI ID to block funds
- Once you approve the same, your funds will be blocked
In Conclusion
The Indian pharma industry is on a growth trajectory and is projected to grow at a CAGR of over 10% to reach USD 130 billion by 2030. In such a scenario, investing in pharma companies can help you create wealth in the long run.
That said, it’s essential to take guard and not go overboard. Before you invest, do due diligence and make sure you are well aware of the associated risks and you can take help of the draft red herring prospectus for it. A well-rounded approach will help you make the most out of your investment.
